Boehringer Ingelheim

Three blocks displaying from left to right a person a handshake and another person
Biotech

Boehringer makes €407M bet on Immunitas’ inflammatory asset

Boehringer secured global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory and autoimmune diseases.
Nick Paul Taylor May 12, 2026 9:57am
obesity overweight weight loss weigh

Boehringer links dual agonist to 16.6% weight loss in phase 3

Apr 28, 2026 4:00am
red and yellow background with scissors

Click cuts staff after commercial deal restructuring

Apr 14, 2026 10:25am
Four white arrows pointing to computer trash can icon

Boehringer, Amgen scrap immunology assets, citing low potential

Apr 14, 2026 4:00am
Medical technology icons and graphics around smartphone screen

Boehringer, Click restructure digital therapeutic sales pact

Apr 9, 2026 9:04am
Paola Casarosa Boehringer

ADCs, TCEs among ‘exciting things’ on Boehringer's shopping list

Apr 3, 2026 8:40am